Pluri Inc. (PLUR) Operating Margin
- Operating margin · 12 months: Value -2454.53%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -2454.53% | Operating income / revenue. Period ending 2026-06-30. $-24.94M ÷ $1.02M × 100 ≈ -2454.53% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -24.94M USD | Operating Income (Loss) |
| Revenue | 1.02M USD | |
| Cost of products and services | (m) | |
| Research and development | 15.09M USD | Research and Development Expense |
| Selling, general and administration | (m) | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-24.94M | $1.02M | (m) | $15.09M | (m) | -2454.53% |
| 2026-03-31 | $-26.01M | $1.08M | (m) | $15.71M | (m) | -2410.84% |
| 2025-12-31 | $-24.88M | $1.34M | (m) | $14.79M | (m) | -1857.88% |
| 2025-09-30 | $-23.33M | $1.33M | (m) | $13.89M | (m) | -1759.28% |
| 2025-06-30 | $-22.18M | $1.34M | (m) | $12.85M | (m) | -1659.88% |
| 2025-03-31 | $-21.59M | $1.03M | (m) | $12.25M | (m) | -2087.91% |
| 2024-12-31 | $-21.72M | $678.00K | (m) | $12.30M | (m) | -3203.98% |
| 2024-09-30 | $-21.98M | $598.00K | (m) | $12.34M | (m) | -3675.42% |
| 2024-06-30 | $-22.16M | $326.00K | (m) | $12.45M | (m) | -6796.93% |
| 2024-03-31 | $-22.67M | $341.00K | (m) | $14.24M | (m) | -6647.51% |
| 2023-12-31 | $-24.23M | $357.00K | (m) | $15.31M | (m) | -6788.24% |
| 2023-09-30 | $-25.70M | $254.00K | (m) | $16.28M | (m) | -10118.11% |
| 2023-06-30 | $-27.25M | $287.00K | (m) | $17.41M | (m) | -9493.38% |
| 2023-03-31 | $-29.58M | $176.00K | (m) | $18.81M | (m) | -16809.09% |
| 2022-12-31 | $-32.96M | $323.00K | (m) | $20.75M | (m) | -10204.02% |
| 2022-09-30 | $-37.08M | (m) | (m) | $22.72M | (m) | (m) |
| 2022-06-30 | $-41.59M | $234.00K | (m) | $24.61M | (m) | -17774.79% |
| 2022-03-31 | $-47.30M | (m) | (m) | $27.71M | (m) | (m) |
| 2021-12-31 | $-51.05M | (m) | (m) | $29.26M | (m) | (m) |
| 2021-09-30 | $-53.33M | (m) | (m) | $30.72M | (m) | (m) |
| 2021-06-30 | $-50.62M | (m) | (m) | $30.53M | (m) | (m) |
| 2021-03-31 | $-44.55M | (m) | (m) | $27.98M | (m) | (m) |
| 2020-12-31 | $-37.72M | (m) | (m) | $25.90M | (m) | (m) |
| 2020-09-30 | $-31.02M | (m) | (m) | $23.47M | (m) | (m) |
| 2020-06-30 | $-29.48M | $23.00K | (m) | $23.10M | (m) | -128156.52% |
| 2020-03-31 | $-28.89M | $23.00K | (m) | $23.40M | (m) | -125621.74% |
| 2019-12-31 | $-31.79M | $23.00K | (m) | $26.08M | (m) | -138234.78% |
| 2019-09-30 | $-33.76M | (m) | (m) | $27.94M | (m) | (m) |
| 2019-06-30 | $-35.53M | $54.00K | (m) | $29.88M | (m) | -65800.00% |
| 2019-03-31 | $-36.38M | $54.00K | (m) | $31.06M | (m) | -67364.81% |
| 2018-12-31 | $-35.13M | $54.00K | (m) | $30.12M | (m) | -65046.30% |
| 2018-09-30 | $-35.26M | $54.00K | (m) | $28.94M | (m) | -65298.15% |
| 2018-06-30 | $-33.73M | $50.00K | (m) | $26.37M | (m) | -67462.00% |
| 2018-03-31 | $-31.54M | (m) | (m) | $24.84M | (m) | (m) |
| 2017-12-31 | $-30.72M | (m) | (m) | $23.94M | (m) | (m) |
| 2017-09-30 | $-28.90M | (m) | (m) | $23.16M | (m) | (m) |
| 2017-06-30 | $-28.02M | (m) | (m) | $24.00M | (m) | (m) |
| 2017-03-31 | $-27.61M | (m) | (m) | $24.52M | (m) | (m) |
| 2016-12-31 | $-26.78M | (m) | (m) | $23.74M | (m) | (m) |
| 2016-09-30 | $-24.36M | (m) | (m) | $23.83M | (m) | (m) |
| 2016-06-30 | $-23.32M | $2.85M | (m) | $22.86M | (m) | -819.07% |
| 2016-03-31 | $-22.96M | $2.94M | (m) | $22.54M | (m) | -780.69% |
| 2015-12-31 | $-23.09M | $3.04M | (m) | $22.93M | (m) | -760.67% |
| 2015-09-30 | $-25.17M | $379.00K | (m) | $22.74M | (m) | -6640.37% |
| 2015-06-30 | $-25.27M | $379.00K | (m) | $23.42M | (m) | -6666.75% |
| 2015-03-31 | $-26.17M | $379.00K | (m) | $23.75M | (m) | -6903.96% |
| 2014-12-31 | $-27.92M | $379.00K | (m) | $24.45M | (m) | -7367.81% |
| 2014-09-30 | $-28.61M | $379.00K | (m) | $25.18M | (m) | -7549.60% |
| 2014-06-30 | $-27.85M | $379.00K | (m) | $24.94M | (m) | -7348.28% |
| 2014-03-31 | $-28.35M | $380.00K | (m) | $25.54M | (m) | -7461.32% |
| 2013-12-31 | $-25.00M | $479.00K | (m) | $23.62M | (m) | -5219.00% |
| 2013-09-30 | $-22.89M | $579.00K | (m) | $21.66M | (m) | -3953.89% |
| 2013-06-30 | $-22.22M | $679.00K | (m) | $19.91M | (m) | -3272.90% |
| 2013-03-31 | $-18.98M | $685.00K | (m) | $16.31M | (m) | -2770.51% |
| 2012-12-31 | $-15.03M | $716.00K | (m) | $12.71M | (m) | -2099.65% |
| 2012-09-30 | $-14.89M | $757.00K | (m) | $13.59M | (m) | -1966.84% |
| 2012-06-30 | $-15.03M | $716.00K | (m) | $12.71M | (m) | -2099.30% |
| 2012-03-31 | $-14.90M | (m) | (m) | $11.75M | (m) | (m) |
| 2011-12-31 | $-12.99M | (m) | (m) | $10.47M | (m) | (m) |
| 2011-09-30 | $-13.69M | (m) | (m) | $9.68M | (m) | (m) |
| 2011-06-30 | $-11.11M | (m) | (m) | $8.31M | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | $-7.44M | (m) | (m) | $6.12M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B |